Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The $200 Popcorn Popper That Keeps Selling Out

October 1, 2026

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Brain Tumor Therapeutics Market Poised for a Significant Growth Spurt, Projected to Reach USD 5.28 Billion by 2030
Press Release

Brain Tumor Therapeutics Market Poised for a Significant Growth Spurt, Projected to Reach USD 5.28 Billion by 2030

By News RoomJanuary 23, 20243 Mins Read
Brain Tumor Therapeutics Market Poised for a Significant Growth Spurt, Projected to Reach USD 5.28 Billion by 2030
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) — The “Global Brain Tumor Therapeutics Market by Type (Glioblastoma, Meningioma, Metastatic Brain Tumors), Therapy (Chemotherapy, Gene Therapy, Immunotherapy), Patient Age Group, Distribution Channel, End-User – Forecast 2024-2030” report has been added to ResearchAndMarkets.com’s offering.

The global landscape for Brain Tumor Therapeutics is experiencing a robust growth phase, with market size estimations indicating a rise to USD 3.03 billion in 2023, and a further growth trajectory expected to lead to USD 5.28 billion by 2030. This demonstrates an impressive compound annual growth rate (CAGR) of 8.24% during the forecast period of 2024-2030. This expansion reflects both the increasing prevalence of brain tumors and significant advancements in therapeutic interventions.

Market Dynamics and Segmentation

The Brain Tumor Therapeutics Market is segmented to provide a detailed understanding of various aspects driving growth. Current trends in the following categories are meticulously evaluated:

  • Type: Evaluating therapeutics for conditions such as Glioblastoma, Meningioma, and Metastatic Brain Tumors.
  • Therapy: Understanding the progress in Chemotherapy, Gene Therapy, and Immunotherapy among other therapeutic approaches.
  • Patient Age Group: Assessing treatment effectiveness across Adult and Pediatric patient groups.
  • Distribution Channel: Analyzing the reach of Offline Vs. Online Pharmacies in the distribution of therapeutics.
  • End-User: Insight into utilization by Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Region: Providing in-depth analysis across diverse geographies including Americas, Asia-Pacific, and Europe, Middle East & Africa.

This compelling report also incorporates a comprehensive glance at market penetration strategies, developmental insights into emerging markets, diversification tactics for product lines and geographies, as well as an in-depth competitive intelligence including market shares and strategic profiles of leaders in the industry.

Key insights regarding technology trends, regulatory landscapes, and potential growth opportunities elucidate factors that are instrumental in shaping the market. The report provides essential insights for companies looking to scale up their operations and for new entrants strategizing to enter the market.

Towards a Future Empowered by Advanced Therapeutics

In an age marked by cutting-edge medical developments, the report on the Brain Tumor Therapeutics Market offers a guide for stakeholders seeking to navigate the complexities of this vital sector. The forecast and analysis it presents are crucial in charting a course for the sustained growth and enhanced patient outcomes the industry strives towards.

For inquiries related to market dynamics, industry trends, or competitive strategies within the Brain Tumor Therapeutics realm, our contribution remains unparalleled. This analysis is an indispensable tool for anyone looking to gain a comprehensive understanding of the brain tumor treatment landscape and the opportunities awaiting therein.

Key Attributes:

Report Attribute Details
No. of Pages 199
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $3.28 Billion
Forecasted Market Value (USD) by 2030 $5.28 Billion
Compound Annual Growth Rate 8.2%
Regions Covered Global

Companies Mentioned

  • AbbVie Inc.
  • Adcendo ApS
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ob2rcu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Brain Tumor Therapeutics Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

The $200 Popcorn Popper That Keeps Selling Out

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

Easy Environmental Solutions Ships First Commercial EasyFEN™ System to Kenya

The News Forum Presents Aftershock: The World After October 7, 2023

BloFin returns as TOKEN2049 Singapore title sponsor, opens its “NEXT WHALE ERA” chapter with 3rd anniversary afterparty

Editors Picks

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026

Latest News

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

October 1, 2026

Police seek answers in crash that killed 2 elders, hurt 2 others on BC First Nation

October 1, 2026

An AI agent tried to hack Canadian government website, researchers say

October 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version